| Health / Medical Topics |
Icrucumab
A fully human IgG1 monoclonal antibody directed against human vascular endothelial growth factor receptor 1 (VEGFR-1/FLT-1) with potential antiangiogenesis and antineoplastic activities. Icrucumab specifically binds to and inhibits the activity of VEGFR-1, which may prevent the activation of downstream signaling pathways and so inhibit tumor angiogenesis; the subsequent reduction in tumor nutrient supply may inhibit tumor cell proliferation. Tumor cell overexpression of VEGFR-1 may be associated with tumor angiogenesis and tumor cell proliferation and invasion; VEGFR-1 may modulate VEGFR-2 signaling. (NCI Thesaurus)
YOU MAY ALSO LIKE
Derived from Rockefeller Swiss mice that were disseminated to the Institute of Cancer Research in Philadelphia (1948). The ICR BR strain is…
An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several…
A polyunsaturated long-chain fatty acid with a 20-carbon backbone and 5 double bonds, originating from the 3rd, 6th, 9th, 12th and 15th…
Human ICOS wild-type allele is located in the vicinity of 2q33 and is approximately 25 kb in length. This allele, which encodes…
This gene is involved in the immune response.
An orally-available synthetic derivative of the beta-amino acid cispentacin with antifungal properties. Icofungipen blocks isoleucyl-tRNA synthetase and results in inhibition of protein…
